In contrast to several other types of cancers in which the Nodal pathway is also re-activated, inhibition of Nodal (and Activin) signalling did not affect tumour cell proliferation or augment cisplatin-sensitivity in TGCTs in vitro or in the xenograft model. The gene discussed is NODAL; the disease is cancer.